WO2004084823A3 - Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof - Google Patents
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof Download PDFInfo
- Publication number
- WO2004084823A3 WO2004084823A3 PCT/US2004/008502 US2004008502W WO2004084823A3 WO 2004084823 A3 WO2004084823 A3 WO 2004084823A3 US 2004008502 W US2004008502 W US 2004008502W WO 2004084823 A3 WO2004084823 A3 WO 2004084823A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tim
- antigen
- domain
- antibodies against
- cell immunoglobulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006507388A JP2007525434A (en) | 2003-03-19 | 2004-03-19 | Antibodies to T cells, immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof. |
AU2004224390A AU2004224390A1 (en) | 2003-03-19 | 2004-03-19 | Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof |
ES04757910.7T ES2557769T3 (en) | 2003-03-19 | 2004-03-19 | Antibodies against the T cell immunoglobulin domain antigen and mucin domain 1 (TIM-1) and uses thereof |
DK04757910.7T DK1613750T3 (en) | 2003-03-19 | 2004-03-19 | ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof |
EP04757910.7A EP1613750B1 (en) | 2003-03-19 | 2004-03-19 | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
CA2519528A CA2519528C (en) | 2003-03-19 | 2004-03-19 | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
AU2010227016A AU2010227016A1 (en) | 2003-03-19 | 2010-10-07 | Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45665203P | 2003-03-19 | 2003-03-19 | |
US60/456,652 | 2003-03-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004084823A2 WO2004084823A2 (en) | 2004-10-07 |
WO2004084823A3 true WO2004084823A3 (en) | 2005-09-15 |
Family
ID=33098138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/008502 WO2004084823A2 (en) | 2003-03-19 | 2004-03-19 | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
Country Status (8)
Country | Link |
---|---|
US (3) | US8067544B2 (en) |
EP (2) | EP1613750B1 (en) |
JP (5) | JP2007525434A (en) |
AU (2) | AU2004224390A1 (en) |
CA (1) | CA2519528C (en) |
DK (1) | DK1613750T3 (en) |
ES (1) | ES2557769T3 (en) |
WO (1) | WO2004084823A2 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001098481A2 (en) | 2000-06-16 | 2001-12-27 | Biogen, Inc. | Renal regulatory elements and methods of use thereof |
WO2002098920A1 (en) | 2001-06-01 | 2002-12-12 | Biogen, Inc. | Molecules and methods for inhibiting shedding of kim-1 |
US8709412B2 (en) | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
SI2357006T1 (en) * | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
NZ593428A (en) * | 2002-09-06 | 2013-01-25 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
ATE403440T1 (en) | 2002-12-30 | 2008-08-15 | Biogen Idec Inc | KIM-1 ANTAGONISTS AND USE FOR IMMUNE SYSTEM MODULATION |
CA2519528C (en) * | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
KR101581040B1 (en) * | 2003-06-27 | 2015-12-30 | 암젠 프레몬트 인코포레이티드 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
CA2543888C (en) | 2003-11-06 | 2016-01-19 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
ATE476994T1 (en) * | 2004-11-30 | 2010-08-15 | Curagen Corp | ANTIBODIES TO GPNMB AND THEIR USES |
BRPI0608254A2 (en) | 2005-03-02 | 2009-12-08 | Biogen Idec Inc | kim-1 antibodies for the treatment of th2 mediated conditions |
US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
EP1858545A2 (en) * | 2005-03-04 | 2007-11-28 | Curedm Inc. | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
WO2006128083A2 (en) | 2005-05-25 | 2006-11-30 | Curedm, Inc. | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
JP2009515897A (en) * | 2005-11-10 | 2009-04-16 | キュラジェン コーポレイション | Methods of treating ovarian and renal cancer using antibodies to immunoglobulin domains of murine domain and mucin domain 1 (TIM-1) antigen |
AU2013206293B2 (en) * | 2005-11-10 | 2016-05-19 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
US8785400B2 (en) * | 2006-11-22 | 2014-07-22 | Curedm Group Holdings, Llc | Methods and compositions relating to islet cell neogenesis |
ES2528922T3 (en) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Humanized and immunoconjugate anti-CD79b antibodies and methods of use |
DK2474557T3 (en) | 2007-07-16 | 2014-11-10 | Genentech Inc | Anti-CD79b antibodies and immune conjugates and methods of use |
EP2193142B1 (en) * | 2007-08-30 | 2015-01-07 | CureDM Group Holdings, LLC | Compositions and methods of using proislet peptides and analogs thereof |
WO2009064290A1 (en) * | 2007-11-13 | 2009-05-22 | Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Structure of tim family members |
AU2009210636B2 (en) | 2008-01-31 | 2014-08-28 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
US20130156784A1 (en) * | 2008-08-20 | 2013-06-20 | Michael Jeffers | Compositions Using Antibodies Directed To GPNMB And Uses Thereof |
WO2010135547A1 (en) * | 2009-05-20 | 2010-11-25 | Celldex Therapeutics, Inc. | Antibodies directed to gpnmb and uses thereof |
AU2012316859A1 (en) * | 2011-09-29 | 2014-04-17 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
AU2013208364B2 (en) | 2012-01-13 | 2017-10-26 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
WO2014018464A1 (en) * | 2012-07-23 | 2014-01-30 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of sepsis |
SI3262071T1 (en) | 2014-09-23 | 2020-07-31 | F. Hoffmann-La Roche Ag | Method of using anti-cd79b immunoconjugates |
SG11201703403TA (en) | 2014-10-27 | 2017-05-30 | Agency Science Tech & Res | Anti-tim-3 antibodies |
GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
WO2018039068A1 (en) * | 2016-08-23 | 2018-03-01 | The Scripps Research Institute | Methods and compositions related to in vivo selection of functional molecules |
EP3568416A4 (en) * | 2017-01-13 | 2020-07-08 | Celdara Medical, LLC | Chimeric antigen receptors targeting tim-1 |
RU2674894C2 (en) * | 2017-01-30 | 2018-12-13 | Общество с ограниченной ответственностью "ПЛАНТА" | New luciferases and methods of their use |
CN109265549A (en) * | 2018-09-25 | 2019-01-25 | 中国人民解放军军事科学院军事医学研究院 | A kind of anti-human Tim-1 antibody with neutralization activity |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997044460A1 (en) * | 1996-05-24 | 1997-11-27 | Biogen, Inc. | Modulators of tissue regeneration |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
DE3218121A1 (en) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Pharmaceutical compositions for tumour treatment |
EP0102324A3 (en) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipids and surfactants in an aqueous medium |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3486459D1 (en) | 1983-09-26 | 1997-12-11 | Udo Dr Med Ehrenfeld | Means and product for the diagnosis and therapy of tumors and for the treatment of weaknesses in cellular and humoral immune defense |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5246692A (en) | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5099069A (en) | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
CA2002910A1 (en) | 1988-11-18 | 1990-05-18 | Motonobu Furuta | Thermoplastic resin composition |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
ES2125854T3 (en) | 1989-08-09 | 1999-03-16 | Rhomed Inc | DIRECT RADIO LABELING OF ANTIBODIES AND OTHER PROTEINS WITH TECNETIO OR RENIUM. |
DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
FR2664073A1 (en) | 1990-06-29 | 1992-01-03 | Thomson Csf | MEANS FOR MARKING OBJECTS, METHOD FOR PRODUCING THE SAME, AND DEVICE FOR READING. |
US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JP2938569B2 (en) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | Method for producing xenogeneic immunoglobulin and transgenic mouse |
WO1992003917A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
EP0592677B1 (en) | 1992-02-18 | 2001-11-07 | Otsuka Kagaku Kabushiki Kaisha | Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2135313A1 (en) | 1992-06-18 | 1994-01-06 | Theodore Choi | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
DE69425890D1 (en) | 1993-06-04 | 2000-10-19 | Us Health | METHOD FOR TREATING KAPOSI SARCOMA WITH ANTISENSE OLIGONUCLEOTIDES |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5622861A (en) | 1994-08-05 | 1997-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA encoding hepatitis A virus receptor |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6025130A (en) | 1996-04-04 | 2000-02-15 | Mercator Genetics, Inc. | Hereditary hemochromatosis gene |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ES2301183T3 (en) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | COMPLETELY HUMAN ANTIBODY THAT JOINS THE EGFR RECEIVER. |
AU7592998A (en) | 1997-05-23 | 1998-12-11 | Biogen, Inc. | Modulators of tissue regeneration |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
CA2382859A1 (en) | 1999-10-07 | 2001-04-12 | Genentech, Inc. | Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
US6849425B1 (en) * | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
WO2002098920A1 (en) | 2001-06-01 | 2002-12-12 | Biogen, Inc. | Molecules and methods for inhibiting shedding of kim-1 |
WO2003002722A2 (en) * | 2001-06-29 | 2003-01-09 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes and methods of use thereof |
EP1461423B1 (en) | 2001-12-03 | 2008-05-14 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
AU2003228336B2 (en) * | 2002-03-19 | 2009-07-30 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
AU2004213053C1 (en) | 2003-02-20 | 2009-07-16 | Seagen Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
CA2519528C (en) | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
WO2005001092A2 (en) * | 2003-05-20 | 2005-01-06 | Wyeth | Compositions and methods for diagnosing and treating cancers |
JP6071725B2 (en) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | Driving force control device for electric vehicles |
US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
2004
- 2004-03-19 CA CA2519528A patent/CA2519528C/en not_active Expired - Fee Related
- 2004-03-19 DK DK04757910.7T patent/DK1613750T3/en active
- 2004-03-19 ES ES04757910.7T patent/ES2557769T3/en not_active Expired - Lifetime
- 2004-03-19 JP JP2006507388A patent/JP2007525434A/en active Pending
- 2004-03-19 AU AU2004224390A patent/AU2004224390A1/en not_active Abandoned
- 2004-03-19 EP EP04757910.7A patent/EP1613750B1/en not_active Expired - Lifetime
- 2004-03-19 EP EP15189243.7A patent/EP3000886A1/en not_active Withdrawn
- 2004-03-19 US US10/805,177 patent/US8067544B2/en not_active Expired - Fee Related
- 2004-03-19 WO PCT/US2004/008502 patent/WO2004084823A2/en active Application Filing
-
2010
- 2010-10-07 AU AU2010227016A patent/AU2010227016A1/en not_active Abandoned
-
2011
- 2011-09-16 JP JP2011203584A patent/JP6103801B2/en not_active Expired - Fee Related
- 2011-11-29 US US13/305,898 patent/US9580503B2/en not_active Expired - Fee Related
-
2014
- 2014-04-14 JP JP2014082974A patent/JP2014144971A/en active Pending
-
2016
- 2016-11-22 JP JP2016226619A patent/JP2017048240A/en not_active Ceased
-
2017
- 2017-02-24 US US15/442,083 patent/US20170218067A1/en not_active Abandoned
-
2018
- 2018-04-10 JP JP2018075311A patent/JP2018150305A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997044460A1 (en) * | 1996-05-24 | 1997-11-27 | Biogen, Inc. | Modulators of tissue regeneration |
US6664385B1 (en) * | 1996-05-24 | 2003-12-16 | Biogen, Inc. | Kidney injury-related molecules |
Non-Patent Citations (2)
Title |
---|
See also references of EP1613750A4 * |
WINTER G. ET AL.: "Humanized antibodies.", IMMUNOL.TODAY., vol. 14, 1993, pages 243 - 246, XP001005438 * |
Also Published As
Publication number | Publication date |
---|---|
CA2519528A1 (en) | 2004-10-07 |
CA2519528C (en) | 2016-01-26 |
JP2012001561A (en) | 2012-01-05 |
US20050084449A1 (en) | 2005-04-21 |
JP2018150305A (en) | 2018-09-27 |
US8067544B2 (en) | 2011-11-29 |
JP2014144971A (en) | 2014-08-14 |
EP1613750A2 (en) | 2006-01-11 |
US20120251555A1 (en) | 2012-10-04 |
EP3000886A1 (en) | 2016-03-30 |
ES2557769T3 (en) | 2016-01-28 |
US9580503B2 (en) | 2017-02-28 |
EP1613750B1 (en) | 2015-10-14 |
DK1613750T3 (en) | 2016-01-18 |
AU2004224390A1 (en) | 2004-10-07 |
US20170218067A1 (en) | 2017-08-03 |
JP2017048240A (en) | 2017-03-09 |
EP1613750A4 (en) | 2008-06-25 |
JP2007525434A (en) | 2007-09-06 |
WO2004084823A2 (en) | 2004-10-07 |
JP6103801B2 (en) | 2017-03-29 |
AU2010227016A1 (en) | 2010-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004084823A3 (en) | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof | |
WO2003057857A3 (en) | Antibodies directed to pdgfd and uses thereof | |
WO2006130458A3 (en) | Antibodies directed to cd20 and uses thereof | |
WO2004050850A3 (en) | Antibodies directed to phospholipase a2 and uses thereof | |
TW200634027A (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
WO2006104978A3 (en) | Antibodies against the tenascin major antigens | |
WO2004050683A3 (en) | Antibodies directed to tumor necrosis factor and uses thereof | |
WO2005118635A3 (en) | Anti-cd3 antibodies and methods of use thereof | |
WO2007120693A3 (en) | Targeted binding agents directed to upar and uses thereof | |
WO2006081139A3 (en) | Antibodies against interleukin-1 beta | |
WO2008112004A3 (en) | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF | |
EP2548583A3 (en) | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen | |
WO2004016769A3 (en) | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof | |
WO2006052591A3 (en) | Anti-properdin antibodies, and methods for making and using same | |
WO2007109307A3 (en) | Antibodies directed to angiopoietin-like protein 4 and uses thereof | |
WO2006124269A3 (en) | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders | |
WO2006055638A3 (en) | Fully human monoclonal antibodies to il-13 | |
WO2007070432A3 (en) | Binding proteins specific for insulin-like growth factors and uses thereof | |
WO2005016111A3 (en) | Antibodies directed to parathyroid hormone (PTH) and uses thereof | |
WO2006055704A3 (en) | Antibodies directed to ten-m proteins and uses thereof | |
WO2006039258A3 (en) | Human antibodies against parathyroid hormone | |
WO1998050433A3 (en) | Human monoclonal antibodies to epidermal growth factor receptor | |
WO2004050032A3 (en) | Antibodies against drugs of abuse | |
WO2008009960A3 (en) | Anti-testosterone antibodies | |
WO2007065037A3 (en) | Antibodies against mmp-13 (collagenase-3) and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2519528 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006507388 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004224390 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004757910 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004224390 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004757910 Country of ref document: EP |